Search

Displaying results 5161 - 5170 of 9670 in total
  1. Drug

    EA-230

    go.drugbank.com/drugs/DB19114
    Investigational

    EA-230 is under investigation in clinical trial NCT03145220 (Immunomodulation of EA-230 Following On-pump Coronary Artery Bypass Grafting (CABG)).

  2. Drug

    Rusalatide

    go.drugbank.com/drugs/DB05309
    Investigational

    TP508 is a non-proteolytic synthetic peptide representing the portion of human thrombin originally identified as the fibroblast high-affinity receptor binding domain.

  3. Drug

    DG051

    go.drugbank.com/drugs/DB05177
    Experimental

    DG051 is a novel small-molecule inhibitor of leukotriene A4 hydrolase (LTA4H), the protein made by one of the genes in the leukotriene pathway that has been shown to link to risk of heart attack.

  4. Drug

    Tariquidar

    go.drugbank.com/drugs/DB06240
    Investigational

  5. Drug

    Procarbazine

    go.drugbank.com/drugs/DB01168
    ApprovedInvestigational

    An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.

  6. Drug

    Tetrahydrocannabivarin

    go.drugbank.com/drugs/DB11755
    Investigational

    It has also shown antiepileptiform and anticonvulsant properties, that suggest possible therapeutic application in the treatment of pathophysiologic hyperexcitability states such as untreatable epilepsy … Although THCV possesses an almost identical structure to Δ9-THC (varying only by the length of its lipophilic alkyl chain), it has different molecular targets and pharmacological profile [A32972].

  7. Drug

    Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen

    go.drugbank.com/drugs/DB10284
    ApprovedInvestigational

    It is contained in the suspension of Trumenba, which is a vaccine is composed of two recombinant lipidated factor H binding protein (fHBP) variants from N. meningitidis serogroup B, one from fHBP subfamily

  8. Drug

    Ty800

    go.drugbank.com/drugs/DB04989
    Investigational

    The Ty800 vaccine was developed using genetic techniques to delete specific genes known to be essential to the virulence of <i>S. typhi</i>. It is being developed by AVANT Immunotherapeutics, Inc.

  9. Drug

    Roquinimex

    go.drugbank.com/drugs/DB11366
    Experimental

    Roquinimex is a derivative of quinoline that presents immunostimulant properties. Its effects are suggested to increase the activity of NK cells and macrophage cytotoxicity. Additionally, roquinimex is known to inhibit angiogenesis and t...

  10. Drug

    MEM 1414

    go.drugbank.com/drugs/DB05888
    Experimental

    It appears to work in the area of the brain where new memories are formed. … This drug candidate has completed Phase 1 clinical trials. MEM 1414 works by blocking phosphodiesterase, an enzyme that breaks down an important brain chemical, cyclic AMP.